Finding into death of J H
Deceased
JH
Demographics
41y, male
Date of death
2023-06-05
Finding date
2026-07-17
Cause of death
Combined effects of mixed drug toxicity (amphetamine, alprazolam, bromazolam, cocaine and metonitazene) and bronchopneumonia
AI-generated summary
JH, a 41-year-old male with ADHD, cirrhosis, and opioid addiction, died from combined drug toxicity involving amphetamine, alprazolam, bromazolam, cocaine, and metonitazene, compounded by bronchopneumonia. Following tattooing on 31 May–1 June 2023 that raised suspicion of cellulitis, he was referred urgently to Box Hill Hospital on 2 June 2023 for assessment of suspected sepsis. Although clinicians recommended continued hospitalisation for two further nights, JH discharged himself after one day against medical advice on 3 June 2023. He was found dead at his Mitcham home on 5 June 2023. Expert toxicology evidence revealed metonitazene (a fentanyl-potency opioid) and bromazolam (an unregulated novel benzodiazepine) in combination with cocaine, producing severe respiratory depression. The case highlights the dangers of novel psychoactive substances purchased from unregulated markets, particularly when combined with CNS depressants and pre-existing respiratory infection. No clinical error by treating clinicians was identified.
AI-generated summary and tagging — may contain inaccuracies; refer to original finding for legal purposes.
Specialties
Drugs involved
Clinical conditions
Contributing factors
- Mixed drug toxicity with combination of CNS depressants and stimulants
- Novel psychoactive substances (bromazolam, metonitazene) from unregulated drug market
- Bronchopneumonia
- Pre-existing respiratory infection (sepsis)
- Opioid addiction and history of unprescribed benzodiazepine use
- Self-discharge against medical advice from Box Hill Hospital
Coroner's recommendations
- Implementation of an early drug warning system to detect and communicate emerging novel psychoactive substance risks in Victoria
- Community education strategies addressing the dangers and risks associated with unregulated drug markets
- Targeted harm-reduction strategies for novel and counterfeit benzodiazepines in unregulated drug markets
Full text
Related cases
Source and disclaimer
This page reproduces or summarises information from publicly available findings published by Australian coroners' courts. Coronial is an independent educational resource and is not affiliated with, endorsed by, or acting on behalf of any coronial court or government body.
Content may be incomplete, reformatted, or summarised. All court orders for redaction and non-publication are respected; documents with technically defective redaction have been excluded from the database entirely. Always refer to the original court publication for the authoritative record.
Copyright in original materials remains with the relevant government jurisdiction. AI-generated summaries and tagging are for educational purposes only, may contain inaccuracies, and must not be treated as legal documents. We welcome feedback for correction —